South & Central America Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The gastrointestinal drugs market in South and Central America is projected to grow significantly, reaching an estimated value of approximately US$ 3,375.85 million by 2031, up from US$ 1,999.39 million in 2023. This growth represents a compound annual growth rate (CAGR) of 6.8% from 2023 to 2031.

Executive Summary and Market Analysis

The South and Central America region encompasses countries such as Argentina, Brazil, and other nations in the area. A key driver of market growth is the increasing geriatric population in these countries. Additionally, advancements in the healthcare sector and heightened research and development activities within the pharmaceutical industry are expected to further stimulate market expansion during the forecast period.

Market Segmentation Analysis

The gastrointestinal drugs market can be segmented based on various criteria, including drug class, application, route of administration, and distribution channel.

1. Drug Class: The market is divided into several categories, including biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share.

2. Application: The market is also segmented by application, which includes conditions such as irritable bowel syndrome (IBS), inflammatory ulcerative colitis, Crohn's disease, gastroenteritis, celiac disease, and others. The irritable bowel syndrome segment was the largest contributor to the market in 2023.

3. Route of Administration: The gastrointestinal drugs market is bifurcated into oral and parenteral routes of administration. The oral route held a larger market share in 2023, reflecting patient preference and convenience.

4. Distribution Channel: The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominated the market share in 2023, indicating a strong reliance on healthcare facilities for medication distribution.

Market Outlook

Gastrointestinal diseases encompass a range of conditions affecting the gastrointestinal tract, including common issues like heartburn, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), gastroenteritis, gastroesophageal reflux disease (GERD), constipation, and diarrhea. These conditions are prevalent and often chronic, affecting a significant portion of the global population. Factors such as sedentary lifestyles, changing dietary habits, and increased stress levels contribute to the rising incidence of these diseases.

A recent study titled "Gastroesophageal Reflux Disease," published in July 2023, highlighted that GERD is one of the most commonly diagnosed gastrointestinal conditions, impacting around 20% of the population. This condition not only imposes a substantial economic burden due to direct and indirect costs but also significantly affects individuals' quality of life. Furthermore, the prevalence of IBS has surged in recent decades, with the International Foundation for Gastrointestinal Disorders reporting that IBS affects 10-15% of the global population. Research from the University of Gothenburg indicates that approximately 40% of adults worldwide experience some form of functional gastrointestinal disorder, underscoring the growing demand for effective treatments and driving the gastrointestinal drugs market.

Country Insights

The South and Central America gastrointestinal drugs market includes Brazil, Argentina, and other countries in the region, with Brazil holding the largest market share in 2023. Rapid urbanization in Brazil has led to significant changes in dietary habits, including increased consumption of sugar-laden beverages, coffee, and processed foods, which have contributed to various digestive disorders such as IBS and constipation.

The aging population in Brazil is also a critical factor influencing market growth. According to the Pan American Health Organization, as of 2022, Brazil had over 30 million individuals aged 60 and above, representing 13% of the total population. This demographic is projected to grow to nearly 50 million by 2030, constituting 24% of the population. By 2050, it is estimated that 36% of Brazil's population will be aged 65 and older. This demographic shift is expected to increase the demand for gastrointestinal healthcare services, as older adults are more likely to experience digestive issues.

The Inflammatory Bowel Disease (IBD) National Patient Registry, initiated by the Brazilian Organization for Crohn's Disease and Colitis (GEDIIB), aims to collect epidemiological data on IBD patients in Brazil. Recent findings indicate that IBD prevalence has surpassed 60 cases per 100,000 inhabitants, particularly in urbanized areas like Sao Paulo and Espirito Santo. This rising incidence of gastrointestinal disorders among the aging population is a significant driver of market growth.

Company Profiles

Key players in the South and Central America gastrointestinal drugs market include major pharmaceutical companies such as Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc. These companies are actively pursuing strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase their market presence.

Product Code: TIPRE00016303

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. South & Central America Gastrointestinal Drugs Market Landscape

4.1 Overview
4.2 PEST Analysis

5. South & Central America Gastrointestinal Drugs Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Cases of Gastrointestinal Diseases
- 5.1.2 Increasing Development of Biologics
5.2 Market Restraints
- 5.2.1 High Cost of Biologics
- 5.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
5.3 Market Opportunities
- 5.3.1 Strategic Initiatives by Companies
5.4 Future Trends
- 5.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
5.5 Impact of Drivers and Restraints:

6. Gastrointestinal Drugs Market - South & Central America Analysis

6.1 South & Central America Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

7. South & Central America Gastrointestinal Drugs Market Analysis - by Drug Class

7.1 Biologics
- 7.1.1 Overview
- 7.1.2 Biologics: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Antidiarrheal and Laxatives
- 7.2.1 Overview
- 7.2.2 Antidiarrheal and Laxatives: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Acid Neutralizers
- 7.3.1 Overview
- 7.3.2 Acid Neutralizers: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Anti-inflammatory Drugs
- 7.4.1 Overview
- 7.4.2 Anti-inflammatory Drugs: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Antiemetic and Antinauseants
- 7.5.1 Overview
- 7.5.2 Antiemetic and Antinauseants: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. South & Central America Gastrointestinal Drugs Market Analysis - by Application

8.1 Irritable Bowel Syndrome
- 8.1.1 Overview
- 8.1.2 Irritable Bowel Syndrome: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Inflammatory Ulcerative Colitis
- 8.2.1 Overview
- 8.2.2 Inflammatory Ulcerative Colitis: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Crohn's Disease
- 8.3.1 Overview
- 8.3.2 Crohn's Disease: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Gastroenteritis
- 8.4.1 Overview
- 8.4.2 Gastroenteritis: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Celiac Disease
- 8.5.1 Overview
- 8.5.2 Celiac Disease: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. South & Central America Gastrointestinal Drugs Market Analysis - by Route of Administration

9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Parenteral
- 9.2.1 Overview
- 9.2.2 Parenteral: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. South & Central America Gastrointestinal Drugs Market Analysis - by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. South & Central America Gastrointestinal Drugs Market - Country Analysis

11.1 South & Central America
- 11.1.1 South & Central America Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
  - 11.1.1.1 Brazil: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.1.1 Brazil: South & Central America Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.1.1.2 Brazil: South & Central America Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.1.1.3 Brazil: South & Central America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.1.1.4 Brazil: South & Central America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.1.1.2 Argentina: South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.2.1 Argentina: South & Central America Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.1.2.2 Argentina: South & Central America Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.1.2.3 Argentina: South & Central America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.1.2.4 Argentina: South & Central America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.1.1.3 Rest of South & Central America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.1.3.1 Rest of South & Central America Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.1.3.2 Rest of South & Central America Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.1.3.3 Rest of South & Central America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.1.3.4 Rest of South & Central America Gastrointestinal Drugs Market Breakdown, by Distribution Channel

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in South & Central America Gastrointestinal Drugs Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Sanofi SA
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GSK Plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Johnson & Johnson
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bausch Health Companies Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 AstraZeneca Plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Co Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AbbVie Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bayer AG
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Pfizer Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms